Related Experiment Videos
[What emergencies arise from anticoagulant therapy?]
Zeitschrift Fur Die Gesamte Innere Medizin Und Ihre Grenzgebiete
|July 1, 1978
Summary
Antithrombotics like fibrinolytics and anticoagulants are effective but carry bleeding risks. Careful patient and physician management is crucial to avoid hemorrhage and thromboembolic events.
Area of Science:
- Pharmacology and Clinical Medicine
Background:
- Antithrombotic therapies, including fibrinolytics, anticoagulants, and aggregation inhibitors, are vital across medical specialties.
- Their mechanisms are understood and often regulated by hepatic parameters.
Purpose of the Study:
- To highlight the potential risk of hemorrhage associated with antithrombotic treatment.
- To discuss factors influencing this risk, including laboratory parameters, physician behavior, and patient compliance.
- To outline strategies for managing antithrombotic therapy discontinuation.
Main Methods:
- Review of antithrombotic mechanisms and associated risks.
- Analysis of factors contributing to hemorrhage.
- Discussion of clinical decision-making for treatment omission and discontinuation.
Main Results:
- Standard laboratory parameters may not always predict hemorrhage risk.
- Physician and patient behavior significantly impacts treatment safety.
- Gradual, staged discontinuation is recommended to prevent thromboembolic relapses.
Conclusions:
- Antithrombotic therapy requires vigilant monitoring beyond routine lab tests.
- Addressing behavioral factors in physicians and patients is essential for safe antithrombotic use.
- Managed discontinuation protocols are necessary to mitigate relapse risks.